Why the study?
Does chlorthalidone therapy improve blood-pressure control at 12 weeks in patients with advanced chronic kidney disease and poorly controlled hypertension?
Does chlorthalidone therapy improve blood-pressure control at 12 weeks in patients with advanced chronic kidney disease and poorly controlled hypertension?
Chlorthalidone effectively improves blood pressure control in patients with advanced chronic kidney disease and poorly controlled hypertension.
Supports chlorthalidone for BP control in advanced CKD hypertension; challenges prior low-certainty evidence against benefit.
Among patients with advanced chronic kidney disease and poorly controlled hypertension, chlorthalidone therapy improved blood-pressure control at 12 weeks as compared with placebo. (Funded by the National Heart, Lung, and Blood Institute and the Indiana Institute of Medical Research; CLICK ClinicalTrials.gov number, NCT02841280.).
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: